Kleiner Perkins Caufield & Byers
Kleiner Perkins Caufield & Byers (KPCB) is committed to helping entrepreneurs build sustainable technology businesses. For over 30 years, KPCB has invested in hundreds of market-defining ventures, many of which have gone public or achieved success through mergers and acquisitions. The firm focuses on new technologies and new applications of technology that will drive high-impact change.
KPCB backed companies include Amazon.com, Citrix, Compaq Computer, Electronic Arts, Genentech, Genomic Health, Genprobe, Google, Hybritech, IDEC Pharmaceuticals, Intuit, Netscape, Ligand Pharmaceuticals, Lotus, Nuvasive, Sun Microsystems, Symantec, Verisign and Xilinx.
Additional information can be found at: www.kpcb.com
For more than 30 years InterWest Partners (www.interwest.com) has partnered with exceptional entrepreneurs to build winning technology and life sciences companies. With more than 200 years of combined operating and investing experience, InterWest’s team has raised $2.8B, completed more than 70 IPOs, and participated in nearly 60 upside acquisitions. Currently investing InterWest X, a $650M fund, the firm continues to believe that providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving company.
Interwest Partners has played a formative role in the success of more than 200 companies, including Anesiva, formerly Corgentech, Aspreva, CIENA, Copper Mountain Networks, Corixa, acquired by GlaxoSmithKline PLC, Cor Therapeutics, Crystal Semiconductor, Cyrix, Epicor Medical, IntraLase, Lightera, Myogen, PlaceWare, Silicon Graphics, SiTera, Spinal Dynamics, Stratacom, TheraSense, Ventritex and Xilinx.
Additional information can be found at: www.interwest.com
Valence Life Sciences
Valence Life Sciences is a leading life sciences investment firm focused on late-stage private and micro-cap public drug development companies. Valence Advantage Life Sciences Fund II’s targeted late-stage investment strategy – in conjunction with the team’s experience, insight, and disciplined approach – has produced successful results for both its investors and portfolio companies.
Valence Advantage Life Sciences Fund II was established in 2012 by Managing Directors, Eric W. Roberts and A. Rachel Leheny, Ph.D. – one of Wall Street’s premier life sciences investment banking and research teams. Eric and Rachel have worked together since 1998. The Valence Advantage investment professionals also include managing directors, Jay Cecil and Scott Morenstein. Together the team has a collective 75 years of experience and has worked on over 200 financing and M&A transactions in the life sciences industry.
Additional information can be found at: www.valencefund.com
Wexford Capital LP is an SEC registered investment advisor with over $4.3 billion of assets under management. The firm, which was formed in 1994, manages a series of hedge funds and private equity funds from its Greenwich, CT headquarters. Wexford manages three hedge funds with over $2.1 billion in AUM: the opportunistic/global macro Wexford Spectrum Fund, the multi-strategy credit oriented Wexford Credit Opportunities Fund and the energy, natural resources and industrials focused Wexford Catalyst Fund. Wexford also manages a series of private equity funds and has invested over $5 billion in private equity investments.
Wexford prides itself on its independent thinking and opportunistic investment style. While Wexford invests in many different sectors, we have particular expertise in bankruptcy/distressed, energy/natural resources, real estate, technology/telecommunications and transportation.
Additional information can be found at: www.wexford.com